Navigation Links
Actelion Pharmaceuticals Announces FDA Approval of Brand Name for Commercially Available VELETRI® (epoprostenol for injection) for Pulmonary Arterial Hypertension
Date:8/25/2010

SOUTH SAN FRANCISCO, Calif., Aug. 25 /PRNewswire/ -- Actelion Pharmaceuticals US, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved the brand name VELETRI® for the company's epoprostenol for injection therapy.  VELETRI has been commercially available since April 2010 as Epoprostenol for Injection for the treatment of moderate to severe pulmonary arterial hypertension (PAH) and PAH associated with the scleroderma spectrum of disease.  Actelion plans to release VELETRI-labeled product by early fourth quarter of 2010.

VELETRI is an improved formulation of epoprostenol that offers greater convenience to patients than other epoprostenol formulations.  VELETRI is stable at room temperature for up to 24 hours when diluted as directed and put into the pump for administration, eliminating the need for ice packs.

"VELETRI is a proven therapy for the treatment of PAH patients who don't respond adequately to conventional treatment, and rounds out a portfolio of therapies designed to address the diverse needs of patients with this chronic and life-threatening disease," said Shal Jacobovitz, president of Actelion Pharmaceuticals US, Inc.  "As the pioneer in PAH, we are committed to transforming the lives of patients by developing efficacious therapies that also offer flexibility and convenience in treatment."

In conjunction with the launch of VELETRI, Actelion opened its fourth PAH patient registry in the United States.  PROSPECT, the registry to PROSPECTively evaluate use of VELETRI in patients with PAH, is a multicenter, observational, U.S.-based registry, which is currently ongoing.

Actelion will also provide further information on VELETRI at the American Heart Association Scientific Sessions 2010 in Chicago with a poster entitled "Biocomparability of Two Formulations of Epoprostenol, Epoprostenol for Injection (ACT-385781A) And Flolan®, Via Pharmacokinetic Assess
'/>"/>

SOURCE Actelion Pharmaceuticals US, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. China Yongxin Pharmaceuticals Reports Second Quarter 2010 Results
2. Jazz Pharmaceuticals Provides Update on FDA Advisory Committee Meeting For JZP-6 (Sodium Oxybate) in Fibromyalgia
3. Cumberland Pharmaceuticals Announces Extension of FDA Review of Acetadote® Supplemental New Drug Application
4. Shareholder Class Action Filed Against SciClone Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
5. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
6. Quark Pharmaceuticals and Major Pharmaceutical Company Enter into Licensing Option Agreement for the p53 Suppressor Drug QPI-1002, the First siRNA Administered Systemically in Human
7. Biostar Pharmaceuticals, Inc. Second Quarter Revenue Increased 46.4% to $19.4 Million
8. Trubion Pharmaceuticals Inc. Reports Second-Quarter and First-Half 2010 Financial Results
9. Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results
10. Ferring Pharmaceuticals FIRMAGON® Joins Race to End Prostate Cancer as Official Sponsor of the Great Prostate Cancer Challenge / Dash for Dad
11. Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015   Aratana Therapeutics, ... therapeutics company focused on the licensing, development and commercialization ... that it will present at the Barclays Global ... at the Loews Miami Beach Hotel in ... St. Peter , M.D., President and Chief Executive Officer ...
(Date:3/4/2015)... 2015  Bayer HealthCare today announced that the ... the company,s Biologics License Application (BLA) for BAY ... seeking FDA approval of the investigational compound, proposed ... A in children and adults. ... to hemophilia A patients who need them," said ...
(Date:3/4/2015)... March 4, 2015  Halyard Health, Inc. (NYSE: ... provided its 2015 outlook and related key planning assumptions. ... Health as we report our fourth quarter results, our ... and CEO. "We executed a smooth separation from Kimberly-Clark ... spin-off. We delivered sales growth and margin improvement in ...
Breaking Medicine Technology:Aratana Therapeutics to Present at the Barclays Global Healthcare Conference 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 3Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 2Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 3Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 4Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 5Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 6Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 7Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 8Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 9Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 10Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 11Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 12Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 13Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 14Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 15Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 16Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 17Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 18Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 19Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 20Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 21Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 22Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 23Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 24Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 25Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 26Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 27Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 28Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 29Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 30Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 31
... 2012  Linkwell Corporation "Linkwell"(OTC:LWLL), a developer, manufacturer and ... today it has entered into a definitive share ... Metamining Nevada, Inc., ("Metamining Nevada") as a wholly ... of its newly issued Series C convertible preferred ...
... Software, Inc. , d/b/a Net Medical Xpress ... 2011 year end financial results. New Mexico Software is ... programs using advanced telemedicine solutions for rural hospitals. The ... for the medical market. The company reported ...
Cached Medicine Technology:Linkwell in Definitive Agreement to Acquire Metamining Nevada, Inc. as Wholly Owned Subsidiary 2Linkwell in Definitive Agreement to Acquire Metamining Nevada, Inc. as Wholly Owned Subsidiary 3Net Medical Xpress Announces 2011 Results 2Net Medical Xpress Announces 2011 Results 3Net Medical Xpress Announces 2011 Results 4
(Date:3/4/2015)... 04, 2015 The print component of ... San Francisco Chronicle with a circulation of approximately 173,000 ... digital component is distributed nationally through a vast social ... sites and partner outlets. To explore the digital version ... Milorganite is composed of heat-dried microbes that have digested ...
(Date:3/4/2015)... Houston, Texas (PRWEB) March 04, 2015 ... blog , Endometriosis can be a painful ... endometrium) starts spreading outside of the uterus leading to ... and their families. Endometriosis can have a terrible effect ... symptoms. It is also the most common cause of ...
(Date:3/4/2015)... March 04, 2015 The popular all-natural ... their new L-Style Revolution™ Program. The customized program provides ... women of all health and fitness levels to follow ... faster than traditional methods. , “We’re really proud to ... plans based on award winning techniques to help people ...
(Date:3/4/2015)... California (PRWEB) March 04, 2015 RapidScale, ... 2015, in Las Vegas, Nevada, on March 16th-18th. They ... RapidScale will have some of its top engineering executives ... advances in the RapidScale solution set. Attendees include William ... Senior Cloud Engineer; and Ryan Turpin, Cloud Support Manager. ...
(Date:3/4/2015)... 2015 SIGVARIS proved innovative ... their first compression therapy collection designed exclusively for men. ... SIGVARIS USA is proud to announce the launch of ... , Constructed from a unique, extremely fine synthetic fiber, ... These socks and thigh-highs offer a tailored look that ...
Breaking Medicine News(10 mins):Health News:Advanced Fertility Center of Texas Brings Awareness to the Month of March-Endometriosis Awareness Month 2Health News:Advanced Fertility Center of Texas Brings Awareness to the Month of March-Endometriosis Awareness Month 3Health News:The Makers of Liporidex, The Popular Sports Nutrition Supplement Brand, Launches Its New L-Style Revolution™ Diet & Exercise Program That Promises Turbo Charged Results 2Health News:Rapidscale to Host First Cloudtalk Events at Channel Partners in Las Vegas 2Health News:Rapidscale to Host First Cloudtalk Events at Channel Partners in Las Vegas 3Health News:Building on the Success of MIDTOWN MICROFIBER, SIGVARIS Expands Popular Compression Collection with Longer Foot Length Offerings 2
... 90-Day Supply of More Than 400,Generic Drugs for ... WOONSOCKET, R.I., Oct. 30 Today,CVS/pharmacy, the ... care savings program aimed at helping the uninsured ... obtain a,CVS/pharmacy Health Savings Pass for a $10 ...
... clocks to summer time on the last Sunday in March ... In return, putting the clocks back in the autumn reduces ... a new Swedish study published in the prestigious New ... have examined how the incidence of myocardial infarction in Sweden ...
... and ... Milk Their Diets, HOUSTON, Oct. 30 The last decade ... seem to go in and out of,fashion like shoulder pads and hemlines. Yet, ... Texas residents --,remain overweight or obese., A new campaign crossing the country, ...
... TeleHealth Services, Inc., a,leading provider of integrated communication ... Barker to the new position of Director of,Marketing. ... research and analysis., After a comprehensive search, ... efforts for its comprehensive line of integrated,hospital television ...
... Arno Therapeutics,Inc. (OTC Bulletin Board: ARNI.OB), a ... the appointment,of William F. Hamilton, Ph.D. to its ... committee. Dr. Hamilton has over 40 years experience ... expertise in the areas of,technology strategy and planning, ...
... by Dr. David Katz, Director of Yale University,s,Prevention Research Center ... in Blood Pressure -, DERBY, Conn., Oct.30 Snacking ... help with weight control, according to a recently,completed pilot study ... overweight adults consumed two KIND Fruit & Nut Delight,Bars per ...
Cached Medicine News:Health News:CVS/pharmacy Announces Pharmacy Health Care Savings Program Targeted at the Uninsured 2Health News:CVS/pharmacy Announces Pharmacy Health Care Savings Program Targeted at the Uninsured 3Health News:Clock-shifts affect risk of heart attack 2Health News:Message to Houston Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Houston Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:TeleHealth Names Matthew K. Barker to New Director of Marketing Position 2Health News:Arno Therapeutics Appoints William F. Hamilton to Board of Directors 2Health News:Arno Therapeutics Appoints William F. Hamilton to Board of Directors 3Health News:Daily Snack Bars May Facilitate Weight Loss 2Health News:Daily Snack Bars May Facilitate Weight Loss 3Health News:Daily Snack Bars May Facilitate Weight Loss 4
... Implants - Anatomically designed to enhance the chin ... the mandible with a high-profile central chin projection. ... the entire mandible, this implant provides a high ... extended arms. Cleft Chin Implants - Designed ...
... FL40 Centrifuge Series from Thermo Electron ... increase your productivity in the lab. ... rotors and accessories for high-volume blood ... IEC CL40 and FL40 Centrifuge Series ...
... Multispeed Series offers unsurpassed versatility and ... 1.2 liter benchtop centrifuge. With its ... and high-speed centrifugation capabilities, the IEC ... need to meet a variety of ...
... CL30 Series from Thermo delivers ... for your low-speed clinical applications. ... exchange system, user-friendly controls, and ... CL30 Series delivers solid performance ...
Medicine Products: